Rituximab induces regression of hepatitis C virus-related membranoproliferative glomerulonephritis in a renal allograft

Nephrology Dialysis Transplantation

Volumn 21, Issue 8, 2006, Pages 2320-2324

  Bestard, Oriol ^a   Cruzado, Josep M ^a   Ercilla, Guadalupe ^b   Gomà, Montse ^a   Torras, Joan ^a   Serón, Daniel ^a   Rama, Inés ^a   Ibernon, Meritxell ^b   Viñas, Odette ^b   Carrera, Marta ^a   Grinyó, Josep M ^a  

^a HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^b HOSPITAL CLÍNIC   (Spain)

Author keywords

Cryoglobulinaemia; Hepatitis C virus; Membranoproliferative glomerulonephritis; Renal transplantation; Rituximab

Indexed keywords

MABTERE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; RITUXIMAB; STEROID; TACROLIMUS; UNCLASSIFIED DRUG;

ACUTE GRAFT REJECTION; ADULT; ANAMNESIS; ARTICLE; CASE REPORT; DRUG WITHDRAWAL; ECHOCARDIOGRAPHY; ELECTRON MICROSCOPY; FEMALE; FOLLOW UP; HEPATITIS C; HEPATITIS C VIRUS; HISTOPATHOLOGY; HUMAN; IMMUNOFLUORESCENCE MICROSCOPY; IMMUNOLOGICAL PROCEDURES; KIDNEY ALLOGRAFT; KIDNEY BIOPSY; MAJOR HISTOCOMPATIBILITY COMPLEX; MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS; OSTEOPENIA; PERICARDITIS; PRIORITY JOURNAL; REMISSION; TREATMENT DURATION; TREATMENT FAILURE; TREATMENT OUTCOME; TREATMENT RESPONSE;

ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIGENS, CD20; B-LYMPHOCYTE SUBSETS; CAPILLARIES; COMPLEMENT C4B; CRYOGLOBULINEMIA; FATTY LIVER; FEMALE; FOLLOW-UP STUDIES; GLOMERULONEPHRITIS, MEMBRANOPROLIFERATIVE; GRAFT SURVIVAL; HEPATITIS C, CHRONIC; HLA ANTIGENS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTERFERON-ALPHA; KIDNEY TRANSPLANTATION; LYMPHOCYTE COUNT; MIDDLE AGED; PEPTIDE FRAGMENTS; POSTOPERATIVE COMPLICATIONS; RECURRENCE; RENAL DIALYSIS; REOPERATION; TRANSPLANTATION, HOMOLOGOUS; VIRAL LOAD; VIREMIA;

EID: 33748049787     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfl266     Document Type: Article

References (27)

1. Crosbie O, Alexander G. Hepatitis C links hepatologists, nephrologists and transplant surgeons. Transplantation 1999; 68: 1094
2. Cruzado JM, Torras J, Gil-Vernet S, Grinyó JM. Glomerulonephritis associated with hepatitis C virus infection after renal transplantation. Nephrol Dial Transplant 2000; 15 [Suppl. 8]: 65-67
3. Cantarell MC, Charco R, Capdevila L et al. Outcome of hepatitis C virus-associated membranoproliferative glomerulonephritis after Ever transplantation. Transplantation 1999; 68: 1131-1134
4. Cruzado JM, Gil-Vernet S, Ercilla G et al. Hepatitis C virus-associated membranoproliferative glomerulonephritis in renal allografts. J Am Soc Nephrol 1996; 7: 2469-2475
5. Cruzado JM, Carrera M, Torras J, Grinyó JM. Hepatitis C virus infection and de novo glomerular lesions in renal allografts. Am J Transplant 2001; 1: 171-178
6. Natov SN, Pereira BJG. Management of hepatitis C infection in renal transplant recipients. Am J Transplant 2002; 2: 483-490
7. Cruzado JM, Casanovas-Taltavull T, Baliellas C, Gil-Vernet S, Grinyó JM. Pretransplant interferon prevents hepatitis C virus-associated glomerulonephritis by HCV-RNA clearance. Am J Transplant 2003; 3: 357-360
8. Pham, HP, Feray C, Samuel D et al. Effects of ribavirin on hepatitis C-associated nephrotic syndrome in four liver transplant recipients. Kidney Int 1998; 54 1311-1319
9. Rostaing L, Izopet J, Baron E, Duffaut M, Puel J, Durand D. Treatment of chronic hepatitis C with recombinant interferon alpha in kidney transplant recipients. Transplantation 1995; 59: 1426-1431
10. Curry MP, Golden-Mason L, Doherty DG el al. Expansion of innate CD5pos B cells expressing high levels of CD81 in hepatitis C virus-infected liver. J Hepatol 2003; 38: 642-650
11. De Vita S, De Re V, Gasparotto D et al. Oligoclonal non-neoplastic B cell expansion is the key feature of type II mixed cryoglobulinemia: clinical and molecular findings do not support a bone marrow pathologic diagnosis of indolent B cell lymphoma. Arthritis Rheum 2000; 43: 94-102
12. Einfeld DA, Brown JP, Valentine MA, Clark EA, Ledbetter JA. Molecular cloning of the human B cell CD20 receptor predicts a hydrophobic protein with multiple transmembrane domains. EMBO J 1988; 7: 711-717
13. Maloney DG, Grillo-Lopez AJ, White CA et al. IDEC-C3B8 (Rituximab) anti CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood 1997; 90:2188-2195
14. Zaja F, Russo D, Fuga G et al. Rituximab in a case of cold agglutinin disease. Br J Hematol 2001; 115: 232-233
15. Zaja F, Russo D, Fuga G, Perella G, Baccarini M. Rituximab for myasthenia gravis developing after bone marrow transplant. Neurology 2000; 55: 1062-1063
16. Sansonno D, De Re V, Lauletta G, Tucci FA, Boiocchi M, Dammacco F. Monoclonal antibody treatment of mixed cryoglobulinemia resisitant to interferon alpha with an anti CD-20. Blood 2003; 101: 3818-3826
17. Zaja F, De Vita S, Mazzaro, C et al. Efficacy and safety of rituximab in type II cryoglobulinemia. Blood 2003; 101: 3827-3834
18. Roccatello, D, Baldovino S, Rossi D et al. Long-term effects of anti-CD20 monoclonal antibody treatment of cryoglobulinemic glomerulonephritis. Nephrol Dial Transplant 2004; 19: 3054-3061
19. Ghijsels E, Lerut E, Vanrenterghem Y, Kuypers D. Anti-CD20 monoclonal antibody (rituximab) treatment for hepatitis C-negative therapy-resistant essential mixed cryoglobulinemia with renal and cardiac failure. Am J Kidney Dis 2004; 43: E34-e38
20. Becker YJ, Becker BN, Pirsch JD, Sollinger HW. Rituximab as treatment for refractory kidney transplant rejection. Am J Transplant 2004; 4: 996-1001
21. Warren DS, Zachary AA, Sonnenday CJ et al. Successful renal transplantation across simultaneous ABO incompatible and positive crossmatch barriers. Am J Transplant 2004; 4: 561-568
22. Gloor JM, DeGoey SR, Pineda AA et al. Overcoming a Positive crossmatch in living-donor kidney transplantation. Am J Transplant 2003; 3: 1017-1023
23. Elstrom RL, Andreadis C, Aqui NA et al. Treatment of PTLD with rituximab or chemotherapy. Am J Transplant 2006; 6: 569-576
24. Basse G, Ribes D, Kamar N et al. Rituximab therapy for de novo mixed cryoglobulinemia in renal transplant patients. Transplantation 2005; 80: 1560-1564
25. Ng HJ, Lim LC. Fulminant hepatitis B virus reactivation with concomitant listeriosis after fludarabine and rituximab therapy: Case report. Ann Hematol 2001; 80: 549-552
26. Selenko N, Majdic O, Jager U, Sillaber C, Stockl J, Knapp W. Cross-priming of cytotoxic T cells promoted by apoptosis-inducing tumor cell reactive antibodies? J Clin Immunol 2002; 22: 124-130
27. Agarwal A, Vieira CA, Book BK, Sidner RA, Fineberg NS, Pescovitz MD. Rituximab, anti CD20, induces In vivo cytokine release but does not impair Ex Vivo T-cell responses. Am J Transplant 2004; 4: 1357-1360